Hyperhidrosis Market: Over 60% of Treated Axillary Patients in Japan Discontinue Therapy, Creating an Opening for Topical Pipeline | DelveInsight
DelveInsight's report sizes the hyperhidrosis market at USD 545 million across the 7MM in 2025, with a 6.6% CAGR forecast through 2036. Only 0.7% of patients with primary focal hyperhidrosis in Japan remained under active medical care, and 62.3% of patients with previously treated primary axillary hyperhidrosis had discontinued treatment, according to DelveInsight's latest Hyperhidrosis Market report. That gap points to a large unmet need that emerging therapies are being developed to address, including ET-01 (Eirion Therapeutics), DMT410 (Dermata Therapeutics/Revance Therapeutics), AT-5214 (dexmecamylamine HCl; Atacama Therapeutics), Oxybutynin/Pilocarpine (ANHYDRIX; Theravida), and others.
LAS VEGAS, Oct. 22, 2026 /PRNewswire/ -- Recently published Hyperhidrosis Market Insights report includes a comprehensive understanding of current treatment practices, hyperhidrosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Hyperhidrosis Market Summary
Discover new treatments for hyperhidrosis @ https://www.delveinsight.com/report-store/hyperhidrosis-market
As per Aparna Thakur, Project Manager of Forecasting at DelveInsight, "ET-01 continues to strengthen its position within Eirion Therapeutics' dermatology pipeline, supported by sustained corporate investment, strategic collaborations, and ongoing clinical development. ET-01's noninvasive topical delivery platform has the potential to address the limitations of injectable botulinum therapies."
Key Factors Driving the Growth of the Hyperhidrosis Market
Download the report to understand the top emerging hyperhidrosis drugs @ Hyperhidrosis Clinical Trials
Hyperhidrosis Market Analysis
Hyperhidrosis Competitive Landscape
Some of the hyperhidrosis drugs under development include ET-01 (Eirion Therapeutics), DMT410 (Dermata Therapeutics/Revance Therapeutics), AT-5214 (dexmecamylamine HCl; Atacama Therapeutics), Oxybutynin/Pilocarpine (ANHYDRIX; Theravida), and others.
Eirion Therapeutics' ET-01 is an investigational topical botulinum toxin formulation being developed by Eirion Therapeutics for the treatment of primary axillary hyperhidrosis. The product employs a proprietary nanoemulsion-based transdermal delivery technology intended to facilitate the passage of botulinum toxin through the skin. This approach may eliminate the pain, bleeding, and bruising commonly associated with injectable botulinum toxin therapies.
ET-01 is currently undergoing Phase II development for primary axillary hyperhidrosis. Its mechanism of action involves blocking acetylcholine release from cholinergic nerve terminals, thereby decreasing stimulation of the eccrine sweat glands and reducing excessive sweating.
Dermata Therapeutics/Revance Therapeutics' DMT410 is an investigational, needle-free topical botulinum toxin delivery platform being developed by Dermata Therapeutics in collaboration with Revance Therapeutics for primary axillary hyperhidrosis (AHH). The treatment integrates Dermata's proprietary XYNGARI technology with Revance's botulinum toxin product, DAXXIFY, to facilitate the topical transport of botulinum toxin across the skin.
DMT410 is being developed as a non-invasive alternative to injectable botulinum toxin treatments, with the potential to reduce injection-related pain, bruising, and discomfort. Preliminary clinical studies have shown promising efficacy and a favorable safety profile, supporting further development of DMT410 as a potential treatment for patients with primary axillary hyperhidrosis.
Theravida's Oxybutynin/pilocarpine is an investigational oral, systemically acting therapy being developed for primary focal hyperhidrosis (PFH), with Phase II clinical development completed. The treatment is formulated as a fixed-dose combination of oxybutynin, a muscarinic receptor antagonist, and pilocarpine, a muscarinic receptor agonist, using proprietary controlled-release technology intended to improve tolerability without compromising efficacy.
The combination is designed to mitigate oxybutynin-associated adverse effects, particularly dry mouth, through the precisely timed release of pilocarpine. By addressing this tolerability concern, oxybutynin/pilocarpine aims to improve treatment adherence and clinical outcomes. In Phase II studies, the therapy demonstrated efficacy across multiple endpoints and produced a statistically significant reduction in dry mouth compared with oxybutynin alone.
The anticipated launch of these emerging therapies are poised to transform the hyperhidrosis market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the hyperhidrosis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
See the hyperhidrosis pipeline by phase and company @ Hyperhidrosis Medications
Hyperhidrosis Market Report Metrics
Details
Study Period
2022–2036
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Hyperhidrosis Market CAGR
6.6 %
Hyperhidrosis Market Size in 2025
USD 545 Million
Key Hyperhidrosis Companies
Eirion Therapeutics, Dermata Therapeutics, Revance Therapeutics, Atacama Therapeutics, Theravida, Journey Medical Corporation/ Maruho, Dr. Wolff Group, Axunio Pharma GmbH, Botanix Pharmaceuticals, Kaken Pharmaceutical, AbbVie, Allergan, Hisamitsu Pharmaceutical, and others
Key Hyperhidrosis Therapies
ET-01, DMT410, AT-5214 (dexmecamylamine HCl), Oxybutynin/Pilocarpine (ANHYDRIX), QBREXZA /RAPIFORT Wipes 2.5%, AXHIDROX, SOFDRA/ECCLOCK Gel, BOTOX, APOHIDE Lotion 20%, and others
What's the Hyperhidrosis Market Report Includes?
DelveInsight's Hyperhidrosis Market Report delivers executive-level intelligence on the evolving market landscape, integrating epidemiology (total, diagnosed, type-, gender-, age- and site-specific prevalent cases), treatment practices, competitive dynamics, emerging therapies, and market forecasts across the major markets through 2036. Built on a rigorous methodology combining comprehensive secondary research, primary interviews with key opinion leaders and industry experts, and proprietary patient-based forecasting models, the report provides a reliable foundation for strategic planning. Designed for pharmaceutical and biotech executives, it enables informed decisions on portfolio strategy, business development, market entry, investment prioritization, and commercial planning.
Request a free sample @ Hyperhidrosis Market Report
Table of Contents
1
Hyperhidrosis Market Key Insights
2
Hyperhidrosis Market Report Introduction
3
Executive Summary of Hyperhidrosis
4
Key Events
5
Epidemiology and Market Forecast Methodology
6
Hyperhidrosis Market Overview at a Glance
6.1
Market Share (%) Distribution of Hyperhidrosis by Therapies in the 7MM in 2026
6.2
Market Share (%) Distribution of Hyperhidrosis by Therapies in the 7MM in 2036
7
Disease Background and Overview
7.1
Introduction
7.2
Types
7.3
Causes and Risk Factors
7.4
Sign and symptoms of Hyperhidrosis
7.5
Pathophysiology of Hyperhidrosis
7.6
Histology
7.7
Diagnosis
7.8
Diagnostic Algorithm of Hyperhidrosis
7.9
Differential Diagnosis of Hyperhidrosis
7.10
Diagnostic guidelines of Hyperhidrosis
7.11
Treatment of Hyperhidrosis
7.12
Types of Treatment for Axillary Hyperhidrosis
7.13
Treatment Algorithm of Hyperhidrosis
7.14
Treatment Guidelines
8
Epidemiology and Patient Population
8.1
Key Findings
8.2
Assumption and Rationale
8.2.1
Total Prevalence Rate of Hyperhidrosis
8.2.2
Type-specific Prevalence Rate of Hyperhidrosis
8.2.3
Age-specific Prevalence Rate of Hyperhidrosis
8.2.4
Gender-specific Prevalence Rate of Hyperhidrosis
8.2.5
Site-specific Prevalence Rate of Hyperhidrosis
8.3
Total Prevalent Cases of Hyperhidrosis in the 7MM
8.4
The US
8.4.1
Total Prevalent Cases of Hyperhidrosis in the US
8.4.2
Total Diagnosed Prevalent Cases of Hyperhidrosis in the US
8.4.3
Type-specific Diagnosed Prevalent Cases of Hyperhidrosis in the US
8.4.4
Gender-specific Diagnosed Prevalent Cases of Hyperhidrosis in the US
8.4.5
Age-specific Diagnosed Prevalent Cases of Hyperhidrosis in the US
8.4.6
Site-specific Diagnosed Prevalent Cases of Hyperhidrosis in the US
8.5
EU4 and the UK
8.6
Japan
9
Patient Journey
10
Marketed Therapies
10.1
Marketed Drugs Competitive Landscape
10.2
QBREXZA /RAPIFORT Wipes 2.5% (glycopyrronium): Journey Medical Corporation/Maruho
10.2.1
Product Description
10.2.2
Regulatory Milestones
10.2.3
Other Developmental Activities
10.2.4
Summary of Pivotal Trials
10.2.5
Analyst's Views
10.3
AXHIDROX (glycopyrronium bromide): Dr. Wolff Group/ Axunio Pharma GmbH
10.4
SOFDRA/ ECCLOCK Gel (sofpironium bromide): Botanix Pharmaceuticals/Kaken Pharmaceutical
10.5
BOTOX (OnabotulinumtoxinA): AbbVie
10.6
APOHIDE Lotion 20% (oxybutynin hydrochloride): Hisamitsu Pharmaceutical
List to be continued in Final report…
11
Emerging Hyperhidrosis Drugs
11.1
Emerging Drugs Competitive Landscape
11.2
Topical ET-01: Eirion Therapeutics
11.2.1
Product Description
11.2.2
Other Developmental Activities
11.2.3
Analyst Views
11.3
DMT410: Dermata Therapeutics/Revance Therapeutics
List to be continued in Final report…
12
Hyperhidrosis Market: The 7MM Analysis
12.1
Key Findings
12.2
Hyperhidrosis Market Outlook
12.3
Attribute Analysis
12.4
Key Hyperhidrosis Market Forecast Assumptions
12.5
Market Size of Hyperhidrosis in the 7MM
12.6
Market Size of Hyperhidrosis by Therapies in the 7MM
12.7
The United States Hyperhidrosis Market Size
12.7.1
Total Market Size of Hyperhidrosis in the US
12.7.2
Market Size of Hyperhidrosis by Therapies in the US
12.8
EU4 and the UK Hyperhidrosis Market Size
12.9
Japan Hyperhidrosis Market Size
13
Unmet Needs
14
SWOT Analysis
15
KOL Views
16
Market Access and Reimbursement
16.1
The United States
16.2
In EU4 and the UK
16.3
Japan
16.4
Market Access and Reimbursement of Hyperhidrosis Therapies
17
Bibliography
18
Hyperhidrosis Market Report Methodology
Related Reports
Hyperhidrosis Clinical Trial Analysis
Hyperhidrosis Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key hyperhidrosis companies, including Eirion Therapeutics, Dermata Therapeutics, Revance Therapeutics, Atacama Therapeutics, Theravida, Journey Medical Corporation/ Maruho, Dr. Wolff Group, Axunio Pharma GmbH, Botanix Pharmaceuticals, Kaken Pharmaceutical, AbbVie, Allergan, Hisamitsu Pharmaceutical, and others.
Axillary Hyperhidrosis Market
Axillary Hyperhidrosis Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key axillary hyperhidrosis companies, including SweatBlock, Certain Dri, Duradry, Zerosweat, Allergan plc., Dermavant Sciences Inc., Botanix Pharmaceuticals Ltd, Dermata Therapeutics Inc, Dr. August Wolff GmbH & Co KG Arzneimittel, Medytox Inc, Revance Therapeutics Inc., and others.
Palmar Hyperhidrosis Market
Palmar Hyperhidrosis Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key palmar hyperhidrosis companies, including GlaxoSmithKline plc., Ulthera, Inc., TheraVida, Dermira, Inc., Brickell Biotech, Inc., Dr. August Wolff GmbH & Co., Revance Therapeutics, Inc., Allergan, Miramar Labs, Inc., and others.
Primary Axillary Hyperhidrosis Market
Primary Axillary Hyperhidrosis Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key primary axillary hyperhidrosis companies, including Brickell Biotech Inc., Dermata Therapeutics LLC, Dr. August Wolff GmbH & Co. KG Arzneimittel, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
SOURCE DelveInsight Business Research, LLP